Skip to main content

Table 1 Characteristics of studies included in the meta-analysis

From: Polymorphisms of TP53 codon 72 with breast carcinoma risk: evidence from 12226 cases and 10782 controls

First Author Publication Year Number of Cases Number of Controls Types of Cases Type of controls Method Country Ref. No.
Själander 1996 212 689 Ductal carcinoma (>80% of the total cases) Pooled individuals from several controls PCR-RFLP Sweden 43
Weston 1997 81 147 NS NS AS-PCR USA 44
Li 2002 28 50 NS 50 healthy people (age-matched) AS-PCR China 45
Wang-Gohrke 2002 577 579 NS NS PCR-RFLP Germany 46
Buyru 2003 115 76 NS 76 healthy people PCR-RFLP Turkey 47
Huang 2003 200 282 NS 282 healthy people PCR-CTPP China 48
Katiyar 2003 77 41 77 Sporadic breast cancer 41 Normal healthy women (age-matched) PCR-RFLP India 49
Mabrouk 2003 30 49 NS NS PCR-RFLP Tunisia 50
Kalemi 2005 42 51 NS 51 healthy women PCR-RFLP UK 51
Tommiska 2005 1827 736 888 unselected breast cancer; 939 familial breast cancer 736 healthy population TaqMan Sweden 52
Baynes 2007 2023 2197 NS NS TaqMan UK 53
Gochhait 2007 576 243 243 sporadic breast cancer; 333 unrelated breast cancer 243 healthy females (ethnically and geographically matched) PCR-RFLP India 54
Khadang 2007 221 205 221 sporadic breast cancer 205 healthy blood donors AS-PCR Iran 55
Schmidt 2007 5191 3834 NS NS TaqMan+ PCR-RFLP UK 56
Sprague 2007 1912 1527 1708 invasive breast cancer; 204 in situ breast cancer 1527 drivers (< 65 year) and roster of Medicare beneficiaries (65–74 year) TaqMan USA 57
Zhang 2007 84 168 NS 168 healthy controls (geographic- and age-matched) PCR-RFLP China 59
Akkiprik 2008 95 107 NS 107 age-matched healthy controls PCR-RFLP Turkey 58
  1. AS-PCR: Allele Specific PCR; RFLP: restriction fragment length polymorphism; CTPP: confronting two-pair primers; NS: not specified